Corticosteroid therapy in IgA nephropathy

Journal of the American Society of Nephrology

Volumn 23, Issue 6, 2012, Pages 1108-1116

  Lv, Jicheng ^a   Xu, Damin ^a   Perkovic, Vlado ^b   Ma, Xinxin ^a   Johnson, David W ^c,d   Woodward, Mark ^b,e   Levin, Adeera ^f   Zhang, Hong ^a   Wang, Haiyan ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b UNIVERSITY OF SYDNEY   (Australia)

^c PRINCESS ALEXANDRA HOSPITAL   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CILAZAPRIL; DIPYRIDAMOLE; METHYLPREDNISOLONE; PLACEBO; PREDNISONE; RAMIPRIL;

ARTICLE; COCHRANE LIBRARY; CONFIDENCE INTERVAL; CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; CUSHINGOID SYNDROME; DIABETES MELLITUS; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EMBASE; GASTROINTESTINAL HEMORRHAGE; GLOMERULUS FILTRATION RATE; HEADACHE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; IMPAIRED GLUCOSE TOLERANCE; INSOMNIA; KIDNEY FAILURE; KIDNEY FUNCTION; LONG TERM CARE; MEDLINE; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; PROTEIN URINE LEVEL; PROTEINURIA; RENAL PROTECTION; SHORT COURSE THERAPY; SIDE EFFECT; STEROID THERAPY; SYSTEMATIC REVIEW; WEIGHT GAIN;

EID: 84861802627     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2011111112     Document Type: Article

References (31)

1. D'Amico G: The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med 64: 709-727, 1987
2. Julian BA, Waldo FB, Rifai A, Mestecky J: IgA nephropathy, the most common glomerulonephritis worldwide. A neglected disease in the United States? Am J Med 84: 129-132, 1988
3. Donadio JV, Grande JP: IgA nephropathy.NEngl J Med347: 738-748, 2002 (Pubitemid 35203906)
4. Nachman PH, Jennette JC, Falk RJ: IgA nephropathy. In: Brenner and Rector's the Kidney, 8th Ed, edited by Brenner BM, Philadelphia, Saunders, 2007, pp. 1024-1032
5. Lv J, Zhang H, Zhou Y, Li G, Zou W, Wang H: Natural history of immunoglobulin A nephropathy and predictive factors of prognosis: A long-term follow up of 204 cases in China. Nephrology (Carlton) 13: 242-246, 2008 (Pubitemid 351341460)
6. D'Amico G: Natural history of idiopathic IgA nephropathy: Role of clinical and histological prognostic factors. Am J Kidney Dis 36: 227-237, 2000
7. Reich HN, Troyanov S, Scholey JW, Cattran DC; Toronto Glomerulonephritis Registry: Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol 18: 3177-3183, 2007 (Pubitemid 350223978)
8. Berthoux F, Mohey H, Laurent B, Mariat C, Afiani A, Thibaudin L: Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol 22: 752-761, 2011
9. Reid S, Cawthon PM, Craig JC, Samuels JA, Molony DA, Strippoli GF: Non-immunosuppressive treatment for IgA nephropathy. Cochrane Database Syst Rev (3):): CD003962, 2011
10. Suzuki H, Fan R, Zhang Z, Brown R, Hall S, Julian BA, Chatham WW, Suzuki Y, Wyatt RJ, Moldoveanu Z, Lee JY, Robinson J, Tomana M, Tomino Y, Mestecky J, Novak J: Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest 119: 1668-1677, 2009
11. Glassock RJ: Analyzing antibody activity in IgA nephropathy. J Clin Invest 119: 1450-1452, 2009
12. Samuels JA, Strippoli GF, Craig JC, Schena FP, Molony DA: Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev (4):): CD003965, 2003
13. Cheng J, Zhang X, Zhang W, He Q, Tao X, Chen J: Efficacy and safety of glucocorticoids therapy for IgA nephropathy: A meta-analysis of randomized controlled trials. Am J Nephrol 30: 315-322, 2009
14. Zhou YH, Tang LG, Guo SL, Jin ZC,WuMJ, Zang JJ, Xu JF, Wu CF,Qin YY, Cai Q, Gao QB, Zhang SS, Yu DH, He J: Steroids in the treatment of IgA nephropathy to the improvement of renal survival: A systematic review and meta-analysis. PLoS ONE 6: e18788, 2011
15. Lai KN, Lai FM, Ho CP, Chan KW: Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: A long-term controlled trial. Clin Nephrol 26: 174-180, 1986 (Pubitemid 16025306)
16. Koike M, Takei T, Uchida K, Honda K, Moriyama T, Horita S, Ogawa T, Yoshida T, Tsuchiya K, Nitta K: Clinical assessment of low-dose steroid therapy for patients with IgA nephropathy: A prospective study in a single center. Clin Exp Nephrol 12: 250-255, 2008
17. Manno C, Torres DD, Rossini M, Pesce F, Schena FP: Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with longterm follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant 24: 3694-3701, 2009
18. Hogg RJ, Lee J, Nardelli N, Julian BA, Cattran D, Waldo B, Wyatt R, Jennette JC, Sibley R,Hyland K, Fitzgibbons L, HirschmanG,Donadio JV Jr, Holub BJ; Southwest Pediatric Nephrology Study Group: Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: Report from the Southwest Pediatric Nephrology Study Group. Clin J Am Soc Nephrol 1: 467-474, 2006
19. Katafuchi R, Ikeda K, Mizumasa T, Tanaka H, Ando T, Yanase T, Masutani K, Kubo M, Fujimi S: Controlled, prospective trial of steroid treatment in IgA nephropathy: A limitation of low-dose prednisolone therapy. Am J Kidney Dis 41: 972-983, 2003 (Pubitemid 36532131)
20. Lv J, Zhang H, Chen Y, Li G, Jiang L, Singh AK, Wang H: Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: A randomized controlled trial. Am J Kidney Dis 53: 26-32, 2009
21. Julian BA, Barker C: Alternate-day prednisone therapy in IgA nephropathy. Preliminary analysis of a prospective, randomized, controlled trial. Contrib Nephrol 104: 198-206, 1993
22. Shoji T, Nakanishi I, Suzuki A, Hayashi T, Togawa M, Okada N, Imai E, Hori M, Tsubakihara Y: Early treatment with corticosteroids ameliorates proteinuria, proliferative lesions, and mesangial phenotypic modulation in adult diffuse proliferative IgA nephropathy. Am J Kidney Dis 35: 194-201, 2000 (Pubitemid 30070839)
23. Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli C, Locatelli F: Corticosteroids in IgA nephropathy: A randomised controlled trial. Lancet 353: 883-887, 1999 (Pubitemid 29126876)
24. Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi GB, Altieri P, Ponticelli C, Locatelli F: Corticosteroid effectiveness in IgA nephropathy: Long-termresults of a randomized, controlled trial. J AmSoc Nephrol 15: 157-163, 2004 (Pubitemid 38020707)
25. Eitner F, Ackermann D, Hilgers RD, Floege J: Supportive Versus Immunosuppressive Therapy of Progressive IgA nephropathy (STOP) IgAN trial: Rationale and study protocol. J Nephrol 21: 284-289, 2008
26. Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151: 264-269, 2009
27. Higgins JP, Green S: Cochrane Handbook for Systematic Reviews of Interventions, Version 5.0.2, The Cochrane Collaboration, 2009. Available at http://www.cochrane-handbook.org. Accessed March 10, 2011
28. Woodward M: Epidemiology: Study Design and Data Analysis, 2nd Ed, Boca Raton, FL, Chapman and Hall/CRC, 2005
29. Thompson SG, Pocock SJ: Can meta-analyses be trusted? Lancet 338: 1127-1130, 1991
30. Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 327: 557-560, 2003 (Pubitemid 37088507)
31. Vandenbroucke JP: Bias in meta-analysis detected by a simple, graphical test. Experts' views are still needed. BMJ 316: 469-470,1998